MEDIA RELEASE
FOR IMMEDIATE RELEASE

19 MAY 2020

BREAKTHROUGH STUDY REVEALS GENE DRIVERS SPECIFIC TO ASIAN LUNG CANCERS

New data on East Asian populations will guide researchers and clinicians to develop novel therapeutic strategies tailored to individual lung cancer patients

LUADs in East Asians show a novel inflamed sub-type and more stable genomes compared with those in Europeans (Copyright: A*STAR’s Genome Institute of Singapore)

SINGAPORE – Singapore scientists have completed one of the largest comprehensive genome studies of Asian lung adenocarcinoma (LUAD). Findings from this landmark study, which were published in February 2020's issue of Nature Genetics, are expected to contribute to the development of personalised medicine for lung cancer treatment and prevention. The study was led by scientists from A*STAR’s Genome Institute of Singapore.
Worldwide, LUAD is the most common type of lung cancer, and is responsible for over one million deaths annually\(^2,3\). It differs markedly between Asians and Europeans as Asian LUAD patients tend to be female, non-smokers, and have more mutations in an important gene known as EGFR\(^4\). Past studies by GIS and NCCS have also revealed that Asian lung cancers have higher level of heterogeneity than their European counterparts\(^5\).

**Findings**

In this study, an inter-disciplinary team of researchers built on the donated clinical samples curated by the LCCS, and sequenced and analysed the largest dataset of LUADs for East Asians (including Singaporeans who formed the majority). The study revealed that the tumour mutation landscape in Asian patients is very unique, and several new genes may be implicated in the development of lung cancers in Asians.

One striking discovery from this study is a unique sub-group of lung tumours that appears specific to Asian lung cancers. This sub-group of lung tumours is more inflammatory in Asian patients compared to European patients, and contains high amounts of immune cells. Considering the increasing use of immunotherapy in cancer treatments, this discovery may lead to a more accurate selection of lung cancer patients who can benefit from this form of treatment.

The comprehensive analyses of the genetic and molecular features of these tumours have provided researchers and clinicians a vista to assess the fingerprint of each lung cancer tumour. Such genomic information will deepen their understanding on how individual patients might respond differently to drug treatments, thus enabling a more precise approach to treating patients in the future. Data from this study is now publicly available via the Singapore Oncology Data Portal (OncoSG) which enables integration, visualisation, analyses, and sharing of cancer genomics datasets in Singapore\(^6\).

Prof Zhai Weiwei, a principal investigator at GIS and senior author of the study, noted, “This study depicted a comprehensive genomic landscape of Asian LUADs, and characterised the complex ethnic differences between Asians and Europeans.”

A/Prof Daniel Tan, Senior Clinician Scientist at GIS and Senior Consultant Medical Oncologist at NCCS, said, “Our study highlights how such deep genetic analysis can improve our ability to predict the behaviour of lung cancers beyond traditional clinical parameters, providing new perspectives in tailoring treatment approaches”.

Prof Patrick Tan, Executive Director of GIS, said, “The findings may lead to new patient stratification approaches to provide better personalised treatment options. Novel therapies may also be developed by combining existing therapies with immunotherapy targeting Asian-specific sub-groups.”

--- END ---
Enclosed:

**ANNEX A** – Notes to Editor on Research Findings  
**ANNEX B** – References

For media queries and clarifications, please contact:

Lyn Lai  
Officer, Office of Corporate Communications  
Genome Institute of Singapore, A*STAR  
Tel: +65 6808 8258  
HP: +65 8755 8759  
Email: laiy@gis.a-star.edu.sg

Gillian Tan  
Senior Executive, Corporate Communications  
National Cancer Centre Singapore (NCCS)  
Tel: +65 6236 9529 / 8157 3671  
Email: gillian.tan@nccs.com.sg

---

**About A*STAR’s Genome Institute of Singapore (GIS)**

The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.

The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.

The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.

For more information about GIS, please visit [www.a-star.edu.sg/gis](http://www.a-star.edu.sg/gis).

**About the Agency for Science, Technology and Research (A*STAR)**

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.
As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR’s R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

Follow us on
Facebook | LinkedIn | Instagram | YouTube

About National Cancer Centre Singapore (NCCS)

National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. www.nccs.com.sg
ANNEX A – NOTES TO EDITOR

The research findings described in this media release can be found in the scientific journal Nature Genetics, under the title, “Genomic landscape lung adenocarcinoma in East Asians” by Jianbin Chen1, Hechuan Yang1,2, Audrey Su Min Teo1, Lidyana Bte Amer1, Faranak Ghazi Sherbaf1, Chu Quan Tan1, Jacob Josiah Santiago Alvarez1, Bingxin Lu1, Jia Qi Lim1, Angela Takano3, Rahul Nahar1, Yin Yeng Lee1, Cheryl Zi Jin Phua1, Khi Pin Chua1, Lisda Suteja4, Pauline Jieqi Chen1, Mei Mei Chang1, Tina Puay Theng Koh5, Boon-Hean Ong6, Devanand Anantham7, Anne Ann Ling Hsu7, Apoorva Gogna8, Chow Wei Too8, Zaw Win Aung9, Yi Fei Lee1,3, Lanying Wang9, Tony Kiat Hon Lim9, Andreas Wilm1, Poh Sum Choi1, Poh Yong Ng1, Chee Keong Toh4, Wan-Teck Lim4,14, Siming Ma1, Bing Lim1, Jin Liu10, Wai Leong Tam1,11,12,13, Anders Jacobsen Skanderup1, Joe Poh Sheng Yeong3,14, Eng-Huat Tan9,4, Caretha L. Creasy15, Daniel Shao Weng Tan1,4,16,* , Axel M. Hillmer1,17,* , Weiwei Zhai1,2,13,18,*

* jointly supervised this work.

1. Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore
2. Key Laboratory of Zoological Systematics and Evolution, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
3. Department of Anatomical Pathology, Singapore General Hospital, Singapore 169608, Singapore.
4. Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.
5. Surgical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.
6. Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore 169609, Singapore.
7. Department of Respiratory & Critical Care Medicine, Singapore General Hospital, Singapore 169854, Singapore.
8. Department of Vascular & Interventional Radiology, Singapore General Hospital, Singapore 169609, Singapore.
9. Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore.
10. Centre for Quantitative Medicine, Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore 169857, Singapore.
11. Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore
12. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Singapore 117597, Singapore
13. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
15. Oncology R&D, GlaxoSmithKline, Collegeville, PA 19426-0989, United States.
16. Cancer Therapeutics Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore.
17. Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany
18. Center for Excellence in Animal Evolution and Genetics, Chinese Academy of Sciences, Kunming 650223, China
ANNEX B – REFERENCES

1. The LCCS was set up in 2007 to bring together the academic and clinical community to improve our understanding of the underpinnings of Asian lung cancer with the funding support from various sources – including Singapore Cancer Syndicate, National Research Foundation Singapore, NCC Research Fund, TrailBlazer Foundation, Singapore Millennium Foundation as well as contribution from industrial partners. Since 2013, research to address this important medical challenge has been supported by the National Research Foundation Singapore and administered by the Singapore Ministry of Health’s National Medical Research Council under the Translational and Clinical Research (TCR) Flagship Programme and Open Fund – Large Collaborative Grant (OF-LCG).